By Katherine Hamilton
Co-Diagnostics withdrew its application to the Food and Drug Administration for a Covid-19 test.
The Salt Lake City diagnostics company said Friday it plans to submit an enhanced version of the test, known as Co-Dx PCR COVID-19 Test. Co-Diagnostics is seeking 501(k) review, which looks at whether a device is safe and effective.
The decision to withdraw is based on discussions Co-Diagnostics had with the FDA about the ability to detect a potential deterioration of one component of the test, related to shelf-life stability, it said. Co-Diagnostics plans to address the issue before re-submitting, it said.
The company aims to collect clinical evaluation data on a new test's performance before submitting it.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 21, 2025 16:32 ET (21:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。